Related Experiment Videos
[Study on cefodizime, a new cephem antibiotic, in the field of pediatrics]
H Sato1, A Narita, K Matsumoto
1Department of Pediatrics, Tokyo Metropolitan Ebara General Hospital.
Insights
Cefodizime (CDZM), a new cephem antibiotic, demonstrated effective serum levels and high urinary excretion rates in pediatric patients. This antibiotic showed a 95.2% clinical efficacy across various infections with minimal adverse effects.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Context:
- Cefodizime (CDZM) is a novel cephem antibiotic evaluated for pediatric use.
- Understanding its pharmacokinetic and pharmacodynamic properties is crucial for effective treatment.
Purpose:
- To assess the serum levels, urine excretion, cerebrospinal fluid penetration, and clinical efficacy of cefodizime in pediatric patients.
- To evaluate the safety and adverse reactions associated with cefodizime administration.
Summary:
- Pharmacokinetic studies revealed dose-dependent serum levels and high urinary recovery rates (71.5%-98.0%) for cefodizime.
- Cefodizime demonstrated penetration into the cerebrospinal fluid, with a concentration of 0.76 microgram/ml.
- Clinical trials showed a 95.2% efficacy rate in treating various pediatric infections, including meningitis, respiratory tract infections, and urinary tract infections.
- Adverse reactions were minimal, with diarrhea reported in one case and minor elevations in liver enzymes (GOT/GPT) in other cases.
Impact:
- Cefodizime exhibits favorable pharmacokinetic properties and significant clinical efficacy in pediatric patients.
- The drug's safety profile suggests it is well-tolerated, with a low incidence of adverse effects.
- These findings support the potential of cefodizime as a valuable therapeutic option for bacterial infections in children.
Abstract:
Experimental and clinical study of cefodizime (CDZM, THR-221), a newly developed cephem antibiotic, was done in the field of pediatrics and the results obtained are summarized as follows: 1. Serum levels and urine excretion were examined after 60-minute drip infusion of CDZM at a dose level of 10 mg/kg to 1 patient, at 20 mg/kg to 4 and at 40 mg/kg to 1. Peak levels in serum were 66.3 micrograms/ml for the 10 mg/kg dose occurring 1 hours after the dose, 118.1 micrograms/ml (mean) for 20 mg/kg, 259.2 micrograms/ml for 40 mg/kg, thus a dose-response was observed. T 1/2's (beta phase) were between 1.17 and 1.69 hours. Urinary recovery rates of the drug were between 71.5% and 98.0% in the first 8 hours after administration. 2. The concentration in the cerebrospinal fluid was 0.76 microgram/ml and the serum level was 380.67 micrograms/ml at 15 minutes after intravenous administration of 433 mg of CDZM to a patient with purulent meningitis. 3. The clinical efficacy rate was 95.2% in a total of 21 cases, i.e., 1 purulent meningitis, 10 respiratory tract infection, 3 whooping cough, 5 urinary tract infection, 1 purulent infection of soft tissues and 1 acute thyroiditis. Diarrhea occurred in 1 case as adverse reactions. Abnormal changes in laboratory test results occurred as 1 case each of slightly elevated GOT.GPT and GOT.